Renasight Clinical Application Review and Evaluation (RenaCARE) Study)

Brief description of study

The main goal of this study is to collect blood or buccal (inside the cheek) swab samples from patients with chronic kidney disease and evaluate if the test, Renasight, can help the study doctor to manage clinical care. The study doctor will decide if Renasight test results will be used toward the patient's care management. Renasight is investigational, which means it is not approved by the Food and Drug Administration (FDA). Renasight is a test to determine if there is a genetic cause for a patient’s kidney disease or if there is increased risk due to family history. The purpose of this study is to evaluate how Renasight helps in the diagnosis and management of patients with chronic kidney disease. Natera will analyze specific genes present in the DNA obtained from the blood or buccal swab samples provided by research subjects to provide additional genetic information about the type of kidney disease a subject may have. Patients undergoing Renasight™ testing are offered optional genetic information sessions in addition to their test results.


Clinical Study Identifier: s22-00166
Principal Investigator: Naveed N. Masani.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.